Liver Cirrhosis
Early initiation of lamivudine helps patients with hepatitis B-related decompensated cirrhosis
Published in Hepatitis Weekly, October 24th, 2005
"Few clinical trials have investigated the use of lamivudine (LAM) in patients with decompensated cirrhosis related to chronic hepatitis B. The aim of the present study was to evaluate the efficacy of extended LAM treatment and to determine the timing of LAM administration in patients with decompensated cirrhosis. A total of 17 patients were treated with LAM 100 mg/day," scientists in South Korea report.
"The mean duration of follow up was 28±8.4 months (range: 14-42 months). All patients were evaluated for evidence of clinical, biochemical and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-10-24)
More Articles from Hepatitis Weekly
- Diagnostics
Phased screening uncovers the antiviral activity of hepatitis C virus therapy - Hepatitis B Therapy
C-13-caffeine breath test detects chronic hepatitis B response to lamivudine - Hepatitis B Therapy
RNA interference fights hepatitis B virus replication in murine models - Hepatitis C Therapy
Serum alpha-fetoprotein levels decline in patients who receive hepatitis C virus therapy - Adverse Drug Reaction
Drugs raise mitochondrial toxicity risk in HIV/hepatitis C-coinfected patients - Alcohol Use
S-adenosylmethionine averts liver cancer growth in alcohol hepatitis models - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
